Appendix Table F25. Clinical outcomes after fesoterodine in patients with an overactive bladder and urgency UI by the urodynamic finding of detrusor overactivity (DO) (results from individual RCT)[180]

Outcome	Predictor of effect	Fesoterodine daily dose	Control treatment	Daily dose of control treatment	Events/ randomized to active	Events/ randomized to control	Relative risk (95% CI)	Absolute risk difference (95% CI)	Number needed to treat	Attributable events/1000 treated
Discontinued	Patients with DO and urgency	4mg	Fesoterodine-extended release	8mg	4/25	6/28	0.75 (0.24; 2.35)	-0.05 (-0.26; 0.15)		
Discontinued	Patients with DO and urgency	4mg	Fesoterodine-extended release	12mg	4/25	4/22	0.88 (0.25; 3.11)	-0.02 (-0.24; 0.19)		
Discontinued	Patients with DO and urgency	4mg	Placebo		4/25	7/24	0.55 (0.18; 1.64)	-0.13 (-0.36; 0.10)		
Discontinued	Patients with DO and urgency	8mg	Placebo		6/28	7/24	0.73 (0.29; 1.89)	-0.08 (-0.31; 0.16)		
Discontinued	Patients with DO and urgency	12mg	Placebo		22/22	7/24	3.26 (1.79; 5.95)	0.71 (0.52; 0.90)	1	708
Discontinued	Patients with DO and urgency	8mg	Fesoterodine-extended release	12mg	6/28	4/22	1.18 (0.38; 3.67)	0.03 (-0.19; 0.25)		
Discontinued	Patients with no DO	4mg	Fesoterodine-extended release	8mg	1/18	3/19	0.35 (0.04; 3.08)	-0.10 (-0.30; 0.09)		
Discontinued	Patients with no DO	4mg	Fesoterodine-extended release	12mg	1/18	1/16	0.89 (0.06; 13.08)	-0.01 (-0.17; 0.15)		
Discontinued	Patients with no DO	4mg	Placebo		1/18	1/19	1.06 (0.07; 15.64)	0.00 (-0.14; 0.15)		
Discontinued	Patients with no DO	8mg	Placebo		3/19	1/19	3.00 (0.34; 26.33)	0.11 (-0.09; 0.30)		
Discontinued	Patients with no DO	12mg	Placebo		1/16	1/19	1.19 (0.08; 17.51)	0.01 (-0.15; 0.17)		

Appendix Table F25. Clinical outcomes after fesoterodine in patients with an overactive bladder and urgency UI by the urodynamic finding of detrusor overactivity (DO) (results from individual RCT)[180] (continued)

Outcome	Predictor of effect	Fesoterodine daily dose	Control treatment	Daily dose of control treatment	Events/ randomized to active	Events/ randomized to control	Relative risk (95% CI)	Absolute risk difference (95% CI)	Number needed to treat	Attributable events/1000 treated
Discontinued	Patients with no DO	8mg	Fesoterodine-extended release	12mg	3/19	1/16	2.53 (0.29; 21.98)	0.10 (-0.11; 0.30)		
Any adverse effects	Patients with DO and urgency	4mg	Fesoterodine-extended release	8mg	22/25	25/28	0.99 (0.81; 1.20)	-0.01 (-0.18; 0.16)		
Any adverse effects	Patients with DO and urgency	4mg	Fesoterodine-extended release	12mg	22/25	20/22	0.97 (0.80; 1.18)	-0.03 (-0.20; 0.15)		
Any adverse effects	Patients with DO and urgency	4mg	Placebo		22/25	16/24	1.32 (0.96; 1.81)	0.21 (-0.01; 0.44)		
Any adverse effects	Patients with DO and urgency	8mg	Placebo		25/28	16/24	1.34 (0.98; 1.83)	0.23 (0.01; 0.45)	4	226
Any adverse effects	Patients with DO and urgency	12mg	Placebo		20/22	16/24	1.36 (1.00; 1.86)	0.24 (0.02; 0.47)	4	242
Any adverse effects	Patients with DO and urgency	8mg	Fesoterodine-extended release	12mg	25/28	20/22	0.98 (0.82; 1.18)	-0.02 (-0.18; 0.15)		
Any adverse effects	Patients with DO and urgency	4mg	Fesoterodine-extended release	8mg	11/25	17/28	0.72 (0.43; 1.24)	-0.17 (-0.43; 0.10)		
Any adverse effects	Patients with DO and urgency	4mg	Fesoterodine-extended release	12mg	11/25	14/22	0.69 (0.40; 1.19)	-0.20 (-0.48; 0.08)		
Any adverse effects	Patients with DO and urgency	4mg	Placebo		11/25	3/24	3.52 (1.12; 11.09)	0.32 (0.08; 0.55)	3	315
Dry mouth	Patients with DO and urgency	8mg	Placebo		17/28	3/24	4.86 (1.62; 14.59)	0.48 (0.26; 0.71)	2	482
Dry mouth	Patients with DO and urgency	12mg	Placebo		14/22	3/24	5.09 (1.69; 15.36)	0.51 (0.27; 0.75)	2	511

Appendix Table F25. Clinical outcomes after fesoterodine in patients with an overactive bladder and urgency UI by the urodynamic finding of detrusor overactivity (DO) (results from individual RCT)[180] (continued)

Outcome	Predictor of effect	Fesoterodine daily dose	Control treatment	Daily dose of control treatment	Events/ randomized to active	Events/ randomized to control	Relative risk (95% CI)	Absolute risk difference (95% CI)	Number needed to treat	Attributable events/1000 treated
Dry mouth	Patients with DO and urgency	8mg	Fesoterodine-extended release	12mg	17/28	14/22	0.95 (0.62; 1.47)	-0.03 (-0.30; 0.24)		
Headache	Patients with DO and urgency	4mg	Fesoterodine-extended release	8mg	5/25	7/28	0.80 (0.29; 2.20)	-0.05 (-0.27; 0.17)		
Headache	Patients with DO and urgency	4mg	Fesoterodine-extended release	12mg	5/25	4/22	1.10 (0.34; 3.59)	0.02 (-0.21; 0.24)		
Headache	Patients with DO and urgency	4mg	Placebo		5/25	5/24	0.96 (0.32; 2.90)	-0.01 (-0.23; 0.22)		
Headache	Patients with DO and urgency	8mg	Placebo		7/28	5/24	1.20 (0.44; 3.29)	0.04 (-0.19; 0.27)		
Headache	Patients with DO and urgency	12mg	Placebo		4/22	5/24	0.87 (0.27; 2.84)	-0.03 (-0.26; 0.20)		
Headache	Patients with DO and urgency	8mg	Fesoterodine-extended release	12mg	7/28	4/22	1.38 (0.46; 4.11)	0.07 (-0.16; 0.30)		
Influenza-like symptoms	Patients with DO and urgency	4mg	Fesoterodine-extended release	8mg	6/25	3/28	2.24 (0.62; 8.03)	0.13 (-0.07; 0.34)		
Influenza-like symptoms	Patients with DO and urgency	4mg	Fesoterodine-extended release	12mg	6/25	3/22	1.76 (0.50; 6.22)	0.10 (-0.12; 0.32)		
Influenza-like symptoms	Patients with DO and urgency	4mg	Placebo		6/25	2/24	2.88 (0.64; 12.90)	0.16 (-0.04; 0.36)		
Influenza-like symptoms	Patients with DO and urgency	8mg	Placebo		3/28	2/24	1.29 (0.23; 7.07)	0.02 (-0.14; 0.18)		
Influenza-like symptoms	Patients with DO and urgency	12mg	Placebo		3/22	2/24	1.64 (0.30; 8.90)	0.05 (-0.13; 0.23)		

Appendix Table F25. Clinical outcomes after fesoterodine in patients with an overactive bladder and urgency UI by the urodynamic finding of detrusor overactivity (DO) (results from individual RCT)[180] (continued)

Outcome	Predictor of effect	Fesoterodine daily dose	Control treatment	Daily dose of control treatment	Events/ randomized to active	Events/ randomized to control	Relative risk (95% CI)	Absolute risk difference (95% CI)	Number needed to treat	Attributable events/1000 treated
Influenza-like symptoms	Patients with DO and urgency	8mg	Fesoterodine-extended release	12mg	3/28	3/22	0.79 (0.18; 3.52)	-0.03 (-0.21; 0.15)		
Dizziness	Patients with DO and urgency	4mg	Fesoterodine-extended release	8mg	0/25	1/28	0.37 (0.02; 8.73)	-0.04 (-0.13; 0.06)		
Dizziness	Patients with DO and urgency	4mg	Fesoterodine-extended release	12mg	0/25	2/22	0.18 (0.01; 3.50)	-0.09 (-0.23; 0.05)		
Dizziness	Patients with DO and urgency	4mg	Placebo		0/25	2/24	0.19 (0.01; 3.81)	-0.08 (-0.21; 0.05)		
Dizziness	Patients with DO and urgency	8mg	Placebo		1/28	2/24	0.43 (0.04; 4.44)	-0.05 (-0.18; 0.08)		
Dizziness	Patients with DO and urgency	12mg	Placebo		2/22	2/24	1.09 (0.17; 7.10)	0.01 (-0.16; 0.17)		
Dizziness	Patients with DO and urgency	8mg	Fesoterodine-extended release	12mg	1/28	2/22	0.39 (0.04; 4.06)	-0.06 (-0.19; 0.08)		
Nausea	Patients with DO and urgency	4mg	Fesoterodine-extended release	8mg	2/25	3/28	0.75 (0.14; 4.11)	-0.03 (-0.18; 0.13)		
Nausea	Patients with DO and urgency	4mg	Fesoterodine-extended release	12mg	2/25	3/22	0.59 (0.11; 3.20)	-0.06 (-0.23; 0.12)		
Nausea	Patients with DO and urgency	4mg	Placebo		2/25	3/24	0.64 (0.12; 3.50)	-0.05 (-0.21; 0.12)		
Nausea	Patients with DO and urgency	8mg	Placebo		3/28	3/24	0.86 (0.19; 3.86)	-0.02 (-0.19; 0.16)		
Nausea	Patients with DO and urgency	12mg	Placebo		3/22	3/24	1.09 (0.25; 4.85)	0.01 (-0.18; 0.21)		

Appendix Table F25. Clinical outcomes after fesoterodine in patients with an overactive bladder and urgency UI by the urodynamic finding of detrusor overactivity (DO) (results from individual RCT)[180] (continued)

Outcome	Predictor of effect	Fesoterodine daily dose	Control treatment	Daily dose of control treatment	Events/ randomized to active	Events/ randomized to control	Relative risk (95% CI)	Absolute risk difference (95% CI)	Number needed to treat	Attributable events/1000 treated
Nausea	Patients with DO and urgency	8mg	Fesoterodine-extended release	12mg	3/28	3/22	0.79 (0.18; 3.52)	-0.03 (-0.21; 0.15)		
Constipation	Patients with DO and urgency	4mg	Fesoterodine-extended release	8mg	1/25	5/28	0.22 (0.03; 1.79)	-0.14 (-0.30; 0.02)		
Constipation	Patients with DO and urgency	4mg	Fesoterodine-extended release	12mg	1/25	4/22	0.22 (0.03; 1.82)	-0.14 (-0.32; 0.04)		
Constipation	Patients with DO and urgency	4mg	Placebo		1/25	0/24	2.88 (0.12; 67.53)	0.04 (-0.07; 0.15)		
Constipation	Patients with DO and urgency	8mg	Placebo		5/28	0/24	9.48 (0.55; 163.15)	0.18 (0.03; 0.33)	6	179
Constipation	Patients with DO and urgency	12mg	Placebo		4/22	0/24	9.78 (0.56; 171.91)	0.18 (0.01; 0.35)	5	182
Constipation	Patients with DO and urgency	8mg	Fesoterodine-extended release	12mg	5/28	4/22	0.98 (0.30; 3.23)	0.00 (-0.22; 0.21)		
Abdominal pain	Patients with DO and urgency	4mg	Fesoterodine-extended release	8mg	2/25	2/28	1.12 (0.17; 7.37)	0.01 (-0.13; 0.15)		
Abdominal pain	Patients with DO and urgency	4mg	Fesoterodine-extended release	12mg	2/25	3/22	0.59 (0.11; 3.20)	-0.06 (-0.23; 0.12)		
Abdominal pain	Patients with DO and urgency	4mg	Placebo		2/25	0/24	4.81 (0.24; 95.25)	0.08 (-0.05; 0.21)		
Abdominal pain	Patients with DO and urgency	8mg	Placebo		2/28	0/24	4.31 (0.22; 85.62)	0.07 (-0.04; 0.19)		
Abdominal pain	Patients with DO and urgency	12mg	Placebo		3/22	0/24	7.61 (0.42; 139.47)	0.14 (-0.02; 0.29)		

Appendix Table F25. Clinical outcomes after fesoterodine in patients with an overactive bladder and urgency UI by the urodynamic finding of detrusor overactivity (DO) (results from individual RCT)[180] (continued)

Outcome	Predictor of effect	Fesoterodine daily dose	Control treatment	Daily dose of control treatment	Events/ randomized to active	Events/ randomized to control	Relative risk (95% CI)	Absolute risk difference (95% CI)	Number needed to treat	Attributable events/1000 treated
Abdominal pain	Patients with DO and urgency	8mg	Fesoterodine-extended release	12mg	2/28	3/22	0.52 (0.10; 2.87)	-0.06 (-0.24; 0.11)		
Diarrhea	Patients with DO and urgency	4mg	Fesoterodine-extended release	8mg	4/25	0/28	10.04 (0.57; 177.65)	0.16 (0.01; 0.31)	6	160
Diarrhea	Patients with DO and urgency	4mg	Fesoterodine-extended release	12mg	4/25	1/22	3.52 (0.42; 29.18)	0.11 (-0.05; 0.28)		
Diarrhea	Patients with DO and urgency	4mg	Placebo		4/25	0/24	8.65 (0.49; 152.58)	0.16 (0.00; 0.32)	6	160
Diarrhea	Patients with DO and urgency	8mg	Placebo		0/28	0/24	0.00 (0.00; 0.00)	0.00 (-0.07; 0.07)		
Diarrhea	Patients with DO and urgency	12mg	Placebo		1/22	0/24	3.26 (0.14; 76.10)	0.05 (-0.07; 0.16)		
Diarrhea	Patients with DO and urgency	8mg	Fesoterodine-extended release	12mg	0/28	1/22	0.26 (0.01; 6.19)	-0.05 (-0.16; 0.07)		
Any adverse events	Patients with no DO	4mg	Fesoterodine-extended release	8mg	14/18	14/19	1.06 (0.73; 1.52)	0.04 (-0.23; 0.32)		
Any adverse events	Patients with no DO	4mg	Fesoterodine-extended release	12mg	14/18	13/16	0.96 (0.68; 1.35)	-0.03 (-0.31; 0.24)		
Any adverse events	Patients with no DO	4mg	Placebo		14/18	17/19	0.87 (0.65; 1.16)	-0.12 (-0.35; 0.12)		
Any adverse events	Patients with no DO	8mg	Placebo		14/19	17/19	0.82 (0.60; 1.12)	-0.16 (-0.40; 0.08)		
Any adverse events	Patients with no DO	12mg	Placebo		13/16	17/19	0.91 (0.69; 1.20)	-0.08 (-0.32; 0.15)		
Any adverse events	Patients with no DO	8mg	Fesoterodine-extended release	12mg	14/19	13/16	0.91 (0.63; 1.30)	-0.08 (-0.35; 0.20)		

Appendix Table F25. Clinical outcomes after fesoterodine in patients with an overactive bladder and urgency UI by the urodynamic finding of detrusor overactivity (DO) (results from individual RCT)[180] (continued)

Outcome	Predictor of effect	Fesoterodine daily dose	Control treatment	Daily dose of control treatment	Events/ randomized to active	Events/ randomized to control	Relative risk (95% CI)	Absolute risk difference (95% CI)	Number needed to treat	Attributable events/1000 treated
Dry mouth	Patients with no DO	4mg	Fesoterodine-extended release	8mg	8/18	8/19	1.06 (0.50; 2.21)	0.02 (-0.30; 0.34)		
Dry mouth	Patients with no DO	4mg	Fesoterodine-extended release	12mg	8/18	10/16	0.71 (0.37; 1.35)	-0.18 (-0.51; 0.15)		
Dry mouth	Patients with no DO	4mg	Placebo		8/18	4/19	2.11 (0.77; 5.81)	0.23 (-0.06; 0.53)		
Dry mouth	Patients with no DO	8mg	Placebo		8/19	4/19	2.00 (0.72; 5.53)	0.21 (-0.08; 0.50)		
Dry mouth	Patients with no DO	12mg	Placebo		10/16	4/19	2.97 (1.15; 7.68)	0.41 (0.11; 0.71)	2	414
Dry mouth	Patients with no DO	8mg	Fesoterodine-extended release	12mg	8/19	10/16	0.67 (0.35; 1.29)	-0.20 (-0.53; 0.12)		
Headache	Patients with no DO	4mg	Fesoterodine-extended release	8mg	3/18	0/19	7.37 (0.41; 133.37)	0.17 (-0.02; 0.35)		
Headache	Patients with no DO	4mg	Fesoterodine-extended release	12mg	3/18	3/16	0.89 (0.21; 3.80)	-0.02 (-0.28; 0.24)		
Headache	Patients with no DO	4mg	Placebo		3/18	3/19	1.06 (0.24; 4.57)	0.01 (-0.23; 0.25)		
Headache	Patients with no DO	8mg	Placebo		0/19	3/19	0.14 (0.01; 2.59)	-0.16 (-0.34; 0.02)		
Headache	Patients with no DO	12mg	Placebo		3/16	3/19	1.19 (0.28; 5.09)	0.03 (-0.22; 0.28)		
Headache	Patients with no DO	8mg	Fesoterodine-extended release	12mg	0/19	3/16	0.12 (0.01; 2.19)	-0.19 (-0.39; 0.02)		
Influenza-like symptoms	Patients with no DO	4mg	Fesoterodine-extended release	8mg	2/18	2/19	1.06 (0.17; 6.72)	0.01 (-0.19; 0.21)		
Influenza-like symptoms	Patients with no DO	4mg	Fesoterodine-extended release	12mg	2/18	1/16	1.78 (0.18; 17.80)	0.05 (-0.14; 0.24)		

Appendix Table F25. Clinical outcomes after fesoterodine in patients with an overactive bladder and urgency UI by the urodynamic finding of detrusor overactivity (DO) (results from individual RCT)[180] (continued)

Outcome	Predictor of effect	Fesoterodine daily dose	Control treatment	Daily dose of control treatment	Events/ randomized to active	Events/ randomized to control	Relative risk (95% CI)	Absolute risk difference (95% CI)	Number needed to treat	Attributable events/1000 treated
Influenza-like symptoms	Patients with no DO	4mg	Placebo		2/18	3/19	0.70 (0.13; 3.73)	-0.05 (-0.27; 0.17)		
Influenza-like symptoms	Patients with no DO	8mg	Placebo		2/19	3/19	0.67 (0.13; 3.55)	-0.05 (-0.27; 0.16)		
Influenza-like symptoms	Patients with no DO	12mg	Placebo		1/16	3/19	0.40 (0.05; 3.44)	-0.10 (-0.30; 0.11)		
Influenza-like symptoms	Patients with no DO	8mg	Fesoterodine-extended release	12mg	2/19	1/16	1.68 (0.17; 16.91)	0.04 (-0.14; 0.22)		
Dizziness	Patients with no DO	4mg	Fesoterodine-extended release	8mg	2/18	0/19	5.26 (0.27; 102.66)	0.11 (-0.06; 0.28)		
Dizziness	Patients with no DO	4mg	Fesoterodine-extended release	12mg	2/18	3/16	0.59 (0.11; 3.11)	-0.08 (-0.32; 0.16)		
Dizziness	Patients with no DO	4mg	Placebo		2/18	2/19	1.06 (0.17; 6.72)	0.01 (-0.19; 0.21)		
Dizziness	Patients with no DO	8mg	Placebo		0/19	2/19	0.20 (0.01; 3.91)	-0.11 (-0.27; 0.06)		
Dizziness	Patients with no DO	12mg	Placebo		3/16	2/19	1.78 (0.34; 9.38)	0.08 (-0.15; 0.32)		
Dizziness	Patients with no DO	8mg	Fesoterodine-extended release	12mg	0/19	3/16	0.12 (0.01; 2.19)	-0.19 (-0.39; 0.02)		
Nausea	Patients with no DO	4mg	Fesoterodine-extended release	8mg	4/18	3/19	1.41 (0.36; 5.43)	0.06 (-0.19; 0.32)		
Nausea	Patients with no DO	4mg	Fesoterodine-extended release	12mg	4/18	4/16	0.89 (0.26; 2.98)	-0.03 (-0.31; 0.26)		
Nausea	Patients with no DO	4mg	Placebo		4/18	5/19	0.84 (0.27; 2.66)	-0.04 (-0.32; 0.23)		
Nausea	Patients with no DO	8mg	Placebo		3/19	5/19	0.60 (0.17; 2.16)	-0.11 (-0.36; 0.15)		
Nausea	Patients with no DO	12mg	Placebo		4/16	5/19	0.95 (0.31; 2.95)	-0.01 (-0.30; 0.28)		

Appendix Table F25. Clinical outcomes after fesoterodine in patients with an overactive bladder and urgency UI by the urodynamic finding of detrusor overactivity (DO) (results from individual RCT)[180] (continued)

Outcome	Predictor of effect	Fesoterodine daily dose	Control treatment	Daily dose of control treatment	Events/ randomized to active	Events/ randomized to control	Relative risk (95% CI)	Absolute risk difference (95% CI)	Number needed to treat	Attributable events/1000 treated
Nausea	Patients with no DO	8mg	Fesoterodine-extended release	12mg	3/19	4/16	0.63 (0.17; 2.41)	-0.09 (-0.36; 0.18)		
Constipation	Patients with no DO	4mg	Fesoterodine-extended release	8mg	1/18	2/19	0.53 (0.05; 5.33)	-0.05 (-0.22; 0.12)		
Constipation	Patients with no DO	4mg	Fesoterodine-extended release	12mg	1/18	3/16	0.30 (0.03; 2.57)	-0.13 (-0.35; 0.09)		
Constipation	Patients with no DO	4mg	Placebo		1/18	2/19	0.53 0.05; 5.33)	-0.05 (-0.22; 0.12)		
Constipation	Patients with no DO	8mg	Placebo		2/19	2/19	1.00 (0.16; 6.38)	0.00 (-0.20; 0.20)		
Constipation	Patients with no DO	12mg	Placebo		3/16	2/19	1.78 (0.34; 9.38)	0.08 (-0.15; 0.32)		
Constipation	Patients with no DO	8mg	Fesoterodine-extended release	12mg	2/19	3/16	0.56 (0.11; 2.96)	-0.08 (-0.32; 0.15)		
Abdominal pain	Patients with no DO	4mg	Fesoterodine-extended release	8mg	0/18	2/19	0.21 (0.01; 4.11)	-0.11 (-0.27; 0.06)		
Abdominal pain	Patients with no DO	4mg	Fesoterodine-extended release	12mg	0/18	3/16	0.13 (0.01; 2.30)	-0.19 (-0.39; 0.02)		
Abdominal pain	Patients with no DO	4mg	Placebo		0/18	2/19	0.21 (0.01; 4.11)	-0.11 (-0.27; 0.06)		
Abdominal pain	Patients with no DO	8mg	Placebo		2/19	2/19	1.00 (0.16; 6.38)	0.00 (-0.20; 0.20)		
Abdominal pain	Patients with no DO	12mg	Placebo		3/16	2/19	1.78 (0.34; 9.38)	0.08 (-0.15; 0.32)		
Abdominal pain	Patients with no DO	8mg	Fesoterodine-extended release	12mg	2/19	3/16	0.56 (0.11; 2.96)	-0.08 (-0.32; 0.15)		
Diarrhea	Patients with no DO	4mg	Fesoterodine-extended release	8mg	1/18	1/19	1.06 (0.07; 15.64)	0.00 (-0.14; 0.15)		

Appendix Table F25. Clinical outcomes after fesoterodine in patients with an overactive bladder and urgency UI by the urodynamic finding of detrusor overactivity (DO) (results from individual RCT)[180] (continued)

Outcome	Predictor of effect	Fesoterodine daily dose	Control treatment	Daily dose of control treatment	Events/ randomized to active	Events/ randomized to control	Relative risk (95% CI)	Absolute risk difference (95% CI)	Number needed to treat	Attributable events/1000 treated
Diarrhea	Patients with no DO	4mg	Fesoterodine-extended release	12mg	1/18	2/16	0.44 (0.04; 4.45)	-0.07 (-0.26; 0.12)		
Diarrhea	Patients with no DO	4mg	Placebo		1/18	2/19	0.53 (0.05; 5.33)	-0.05 (-0.22; 0.12)		
Diarrhea	Patients with no DO	8mg	Placebo		1/19	2/19	0.50 (0.05; 5.06)	-0.05 (-0.22; 0.12)		
Diarrhea	Patients with no DO	12mg	Placebo		2/16	2/19	1.19 (0.19; 7.50)	0.02 (-0.19; 0.23)		
Diarrhea	Patients with no DO	8mg	Fesoterodine-extended release	12mg	1/19	2/16	0.42 (0.04; 4.23)	-0.07 (-0.26; 0.12)		

DO=detrusor overactivity